Skip to main content
Past Event

The Cost and Value of Biomedical Innovation: Implications for Health Policy

Past Event

Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation

Play Video
Now Playing

Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation

Play Video
Now Playing

What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies

Play Video
Now Playing

How Do We Ensure Future Innovation? Financing Breakthrough Therapies

High-cost drugs and devices that address significant unmet medical needs have generated much attention lately. New treatments for many cancers and for infections like Hepatitis C have the potential to increase life expectancy and quality of life for affected patients. Many more such treatments are in development. While a number of important breakthroughs have occurred in the past several decades, the increasing ability to target treatments based on a better understanding of genomics, systems biology, and other biomedical sciences could lead to more technologies with broader effects for targeted populations. Thus, biomedical innovation may have substantial future implications for population health and health care costs.

On October 1, the Engelberg Center for Health Care Reform and the USC Schaeffer Center for Health Policy and Economics hosted a half-day forum to discuss the serious coverage challenges that accompany breakthrough treatments, such as the much-discussed new treatment for Hepatitis C, Sovaldi. Researchers presented economic modeling simulations that illustrate the value and long-term effects of such treatments; and exploring potential policy solutions for financing  biomedical innovations.

Agenda

Are New Breakthrough Treatment Worth Their Price? Assessing the Social Costs and Benefits of Biomedical Innovation

D

Douglas Dieterich

Professor of Medicine; Director, Continuing Medical Education - Mount Sinai School of Medicine

What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies

Darius Lakdawalla

Quintiles Chair in Pharmaceutical Development and Regulatory Innovation; - USC Schaeffer Center for Health Policy & Economics

Professor - USC School of Pharmacy and Price School of Public Policy

R

Ryan Clary

Executive Director - National Viral Hepatitis Roundtable

S

Sam Nussbaum

Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.

Break

Darius Lakdawalla

Quintiles Chair in Pharmaceutical Development and Regulatory Innovation; - USC Schaeffer Center for Health Policy & Economics

Professor - USC School of Pharmacy and Price School of Public Policy

R

Ryan Clary

Executive Director - National Viral Hepatitis Roundtable

S

Sam Nussbaum

Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.

How Do We Ensure Future Innovation? Financing Breakthrough Therapies

T

Tomas Philipson

Daniel Levin Professor of Public Policy Studies - University of Chicago

C

Chris Koller

Rhode Island Office of the Health Insurance Commissioner

Closing Remarks

Welcome

More Information

More

Get a weekly events calendar from Brookings